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In response to a request from Martha Stone to review the data bases 
currently available in the area of biotechnology, the following report 
was submitted. 
Trying to define biotechnology is itself a problem. It is a truly 
multi-disciplinary field covering a wide range of disciplines (biology, 
chemistry, agriculture, energy, pharmaceuticals, water and industry, food 
and feedstuffs). Thus its literature cornes in a variety of formats and 
is scattered across all subjects. The popularity of this concept and the 
resulting explosion of articles, reports and patents in this area has 
exacerbated the problem of literature searching of biotechnology. 
Data bases specializing in biotechnology have only been in existence 
for a short time. Just two years ago, only DERWENT BIOTECHNOLOGY 
ABSTRACTS and TELEGENLINE were available as international public access 
systems. Today, reference sources and vendors' catalogues identify 4 
other data bases focusing on this topic: ABSTRACTS IN BIOCOMMERCE (ABC), 
CURRENT BIOTECHNOLOGY ABSTRACTS, BIOTECHNOLOGY INVESTMENT OPPORTUNITIES 
and BIOBUSINESS. 
The following paragraphs outline the features for each data base, 
their strengths and weaknesses. Appendix I reproduces sample records 
from 4 of these specialized tools. 
DERWENT BIOTECHNOLOGY ABSTRACTS - is available online only to 
subscribers at the cost of about $500 per year. This subscription 
fee covers the cost of the printed monthly abstract and permits 
access to the data base which costs about $100/hour tu search. Over 
9,000 entries are included in this file with about 600 new records 
added each month. Entries date from January 1983. Ail aspects of 
biotechnology are covered. Approximately 1000 of the world's 
leading scientific and technical journals as well as conference 
reports and patents are covered. It is available through Orbit. 
The main drawbacks of this data base are: lack of coverage of 
commercial news reports, the subscription fee and its small size. 
2 
TELEGENLINE - Based on the printed publication Telegen Reporter, 
this data base covers scientific journal and report literature and 
commercial news material. It is reported that this is the only data 
base to cuver sonne biotechnology conferences without published 
proceedings. Some patente (US only) are included from April 1983. 
Records do go bock to 1973 but only in amall numbers. Abstracts are 
included for entries since March 1982. Abstracts include a 
statement of the document type (research report, news feature etc). 
Descriptive phrases are added. A strength of this data base is its 
ability to provide full texte of nome documents. It is supposed to 
be particularly strong in genetic engineering. Updated monthly, 
there are more than 6000 entries in the file. No subscription fee 
is changed however on-line access costa $95 per contact hour. 
Available on Dialog and ESA. The Head of Reference et CISTI 
believes that this data base is une of the best available in this 
subject ares. 
ABSTRACTS IN BIUCOMERCE - is currently available only in the United 
Kingdom and concentrates on the trade press especially newsletters. 
Few abstracts of patents or scientific research are included. 
Abstracts are fairly short. Entries begin with March 1981 end 
number about 4000. Descriptors are not added. This data base 
concentrates mainly on genetic engineering and monoclonal 
antibodies. Private file service is available. Short comings of 
this data base are its small size, limited accessibility and 
scarceness of scientific research. 
CURRENT BIOTECHNOLOGY ABSTRACTS - Begun in May 1983 by the United 
Kingdom's Royal Society of Chemistry, this file is available through 
the European Space Agency. It covers about 200 scientific and trade 
sources. The abstracts are-split principally into TECHNOCOMMERCIAL 
DATA (ie business news), TECHNIQUES (genetic manipulations, 
fermentation etc), INDUSTRIAL AREAS (pharmaceuticals, agriculture, 
energy) and INFORMATION (books, reviews). The file site numbers 
about 7000 references with monthly updates around 400 references. 
Short abstracts are prepared directly from the original sources but 
additional abstracts if available are taken from entries in other 
data bases eg. BIOLOGICAL ABSTRACTS. Controlled terme and a unique 
classification system are other features. With an hourly rate of 
only $75 this data base is reasonably priced. Its only weakness is 
its lack of e large backfile for retrospective searches. 
BIOTE HNOLOGY INYESTlENT O ORTUNITIES - is a full text data base 
containing the full text of Biotechnology Investment Opportunities, 
a newsletter on investment opportunities in genetic engineering. 
Company profiles, current research and government policies are 
included. Coverage is International but with little developing 
country focus. It is available through Newsnet. 
3 
BIOBUSINESS - On April 15, 1985, Biosciences Information Service 
(BIOSIS) and the Information Access Company (IAC) announced the 
creation of BIOBUSINESS. It is designed to provide information to 
business executives and product development people on the business 
opportunities of biotechnology research. Over 1100 serials will be 
scanned. The date base will contain over 28,000 records. Available 
this sommer on major date base vendors, this file will provide fully 
indexed references and abstracts. 
To compare these data bases, two topics 
1) cell and tissue culture as applied to agriculture 
2) fermentation as applied to antibodies, vaccines and tropical 
diseases 
were tested on DERWENT BIOTECHNOLOGY ABSTRACTS, TELEGENLINE and CURRENT 
BIOTECHNOLOGY ABSTRACTS. The other data bases were not accessible either 
through IDRC's Library or CISTI. In addition the saure searches were 
performed on a number of other data bases covering agriculture, health 
and science to ascertain overall coverage of these topics. 
Search terms were selected from Mr. Hulse's review paper on 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































- 10 - 
Although the new specialized data bases promise comprehensive 
coverage of biotechnology, as the results of the searches demonstrate, 
they are by no means comprehensive in scope or coverage. The older data 
bases provided access to more references than the 3 specialized sources. 
With these specialized data bases there is overlap and duplication in 
some areas (scientific literature found in the tore journals) end spotty 
coverage in others (developing country literature). No single date base 
can be used as the only source. In fact it has been recommended in data 
base searchinq literature that searchers working on biotechnology related 
questions should aearch several sources to ensure the most complete 
results eg. both TELEGENLINE and DERWENT BIOTECHNOLOGY ABSTRACTS. In 
addition, being so new, these specialized date bases do not have the 
extensive backfiles available from other sources like BIOLOGICAL 
ABSTRACTS (1969- ), MEDLINE (1966- ) and'CAB (1973- ). 
Other factors to be considered when looking et these data bases 
included: 
1) document delivery - how easily could researchers in developinq 
countries obtain copies of listed documents 
2) language of publication - in many of the data bases, much of the 
literature is in Japanese, Russian and German - do researchers in 
developinq countries read these languaaes or have easy access to 
translation services 
3) costs - access to these data bases is not cheap 
4) variety of hosts - in searchinq the test questions, no single 
host supplied all relevant sources. The European Space Agency, 
Orbit and Dialog were ail accessed. 
5) the largest proportion of materiais covered by these data bases 
focused on scientific research. Very few documents referred to 
ethical, safety or legal aspects of biotechnology 
6) developing country coverage - in almost every case developing 
country material was scarce (exceptions CAB, FAIREC, and TROPAG). 
My commenta up to this part have focused on only bibllographic data 
bases however patent data bases, sequence databanks and culture 
collections are ail important sources for biotechnology. 
There are no patent data bases devoted solely to biotechnology 
however as previously mentioned DERWENT BIOTECHNOLOGY ABSTRACTS and 
CURRENT BIOTECHNOLOGY ABSTRACTS do include basic patents. WPI end the 
INPADOC files are also useful. 
DNA and protein sequence data banks do exist. GENBANK end the 
European Molecular Biology Laboratory Nucleotide Sequence Data Library 
are two sources. 
- 11 - 
The ares of culture collections of micro-organisme or cell lines 
will likely be an ares of data base growth in the future. For instance 
CODATA has created a date base entirely on hybridomes ("a cell culture 
consistinq of a clone of fused (hybrid) celle of different kinds") end 
monoclonal antibodies. Its name is CODATA-IUIS HYBRIDOMA DATA BANK: A 
DATA BANK ON CLONED CELL LINES AND THEIR IMMUNDREACTIVE PRDDUCTS. 
On-line access is not yet available but requests cen be submitted for 
searches. There is no charge for this service. Coverege is 
international. The data base has 151 searchable fields end contains 
approximately 3000 records. 
New information sources for biotechnology are constantly beinq 
created. For exemple, just recently Eugene Garfield's Institute for 
Scientific Information produced the ISI - Atlas of Science: Biotechnology 
and Moleculer Genetics. Britein's Science Reference Library is currently 
working on a one year project "European Biotechnology Information 
Project" to evaluate information needs and resources of the European 
Community in this ares. This project involves an on-line system for 
placing enquiries with the SRL and may also include the creation of data 
bases concerned with the Librery's patent and book holdings. 
This short paper is not on an in-depth analysis of biotechnology 
data bases but I hope it will provide some insight into the variety of 
sources available. I would be pleased to answer any questions or provide 
clarification or additional information or any of the topics covered. 
APPENDIX 1 
SALLE RECORDS fROI THE BIOTECHNOLOGY DATA BASES 
DERWENT BIOTECHNOLOGY ABSTRACTS (ON ORBIT) 
-1- 
AN - Et5-039E5 
CL - L (En) E4 
TI - In vitro Plantlet reseneration from :uvenile and mature Çuercus robur- L. 
ST - Plant propaeation 
AU - Vieite: A M' C; Vieitez E 
LO - -Plant PhvEiolo9Y, CSIC, Arartado 122e Santia9c' de Compostela, 
JL - JHSCA8; J.Hortic.Sci.; (1985) 60, 1, 99-106 
IW - En9lish cak seedline and stumr sprout ProPaeation, culture medium effect 
AB - EmbrYos and shoot aPices from 3-4 month old seedlines and stumP sProuts 
of Guercus robur were used to establish shoot cultures in medium 
containine 1 me/1 benzvladenine (BA). Shoot tirs of initial cultures of 
mature trees were subcultured, and best shoot multiplication agas observed 
usin9 Heller's medium with 1 mM ammonium sulfate: or Greshof and Dor's 
medium. BA at 0.1 me/1 enhanced shoot erowth. The basal ends of in 
vitro reeenerated shoots were dipped in 0.5-1% 9/1 indolebutyric acid 
(IBA) for 2-10 min, and then trans-ferred to auxin-free aear medium. 
Rootine rates of 83% and 63% were obtained from juvenile-a and 
adult-derived shoots respectively,. (29 ref) 
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Celltech bas appointed Sumitomo as its 
exclusive agent in Japan. The,company plans 
to a significant impact in Japan on the 
diagnostics mari::et over the short and medium 
term with monoclonal antibodies in kits using 
the IRMA system and other assays, which will 
be developed by the company in the future. 
The Japanese diagnostics market is estimated 
at £200M. Sumitomo is also selling Celltech's 
anti alpha interferon for purification and 
assays and, currently, Celltech is developing 
products to purify and assay beta and gamma 
i nterferons. Sumitomo i s to work: towards 
introducing Celltech's ABO blond grouping 
reagents in Japan and will promote Celltech's 
contract research services, which include 
recombinant DNA technology, gene synthesis, 
metabolic conversions, genome mapping, 
hybridoma technology and the contract 
production o4 monoclonal antibodies. 
Celltech Press felease OCTB2 
Scrip 250CT82 
European Chemical News O1NOVB2 
Guardian 190CT82 
Daily Telegraph 2000T82 
Biotechnology News 15NOV82 
Observer 14NOV92 
BioEngineering News O1NOVB2 
Genetic Technology News DEC62 
Genet i c Eng i ns.rifq i.sttsr 10«C82 
APPENDIX I 
CURRENT BIOTECHNOLOGY ABSTRACTS (ON ESA) 
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APPENDIX II 
KEYWORD LISTING FUR TEST QUESTIONS 
QUESTION I 
Set 1 Set 2 
tissue culture plant* 
plant cela culture flower* 





Combine sets 1 and 2. 




biotechnology tropical medicine 
tropical diseases 
nomes of individual diseases 
Combine sets 1 and 2. 
Additional terms in French were used as PASCAL. 
